Mallinckrodt's subsidiary, SpecGx, will offer refunds to covered entities for over 30 years of overcharges.
SpecGx to Offer Covered Entities Refunds for a Record 30-Plus Years of 340B Overcharges
SpecGx, a generic subsidiary of Mallinckrodt Pharmaceuticals, will refund 340B covered entities that purchased addiction treatment medication Methadose for above [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at [email protected].
